-
Product Insights
NewNet Present Value Model: BeiGene Ltd’s Ociperlimab
Empower your strategies with our Net Present Value Model: BeiGene Ltd's Ociperlimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: BeiGene Ltd’s Sonrotoclax
Empower your strategies with our Net Present Value Model: BeiGene Ltd's Sonrotoclax report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of BeiGene Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of BeiGene Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CDK4 Inhibitor in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CDK4 Inhibitor in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CDK4 Inhibitor in Breast Cancer Drug Details: The therapeutic candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ropidoxuridine in Sarcomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ropidoxuridine in Sarcomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ropidoxuridine in Sarcomas Drug Details: Ropidoxuridine is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surzebiclimab in Hypopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surzebiclimab in Hypopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surzebiclimab in Hypopharyngeal Cancer Drug Details: Surzebiclimab (BGBA-425) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surzebiclimab in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surzebiclimab in Laryngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surzebiclimab in Laryngeal Cancer Drug Details: Surzebiclimab (BGBA-425) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Surzebiclimab in Oropharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Surzebiclimab in Oropharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Surzebiclimab in Oropharyngeal Cancer Drug Details: Surzebiclimab (BGBA-425) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBL-514 in Cellulite
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBL-514 in Cellulite report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBL-514 in Cellulite Drug Details: CBL-514 is under development for the treatment to...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mezagitamab in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mezagitamab in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mezagitamab in Refractory Multiple Myeloma Drug Details: Mezagitamab (TAK-079) is under...